摘要: The treatment of acute myeloid leukemia has improved in the last ten years, and this perspective article Dr. Estey examines recent progress field. See related articles on pages 54 102.
haematologica.org
sci-hub.se 参考文章(28)
Marcos de Lima, Sara S. Strom, Michael Keating, Hagop Kantarjian, Sherry Pierce, Susan O'Brien, Emil Freireich, Elihu Estey, Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. ,vol. 90, pp. 4719- 4724 ,(1997) , 10.1182/BLOOD.V90.12.4719
Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth, David H. Harrington, Karl S. Theil, Anwar Mohamed, Elizabeth Paietta, Cheryl L. Willman, David R. Head, Jacob M. Rowe, Stephen J. Forman, Frederick R. Appelbaum, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood. ,vol. 96, pp. 4075- 4083 ,(2000) , 10.1182/BLOOD.V96.13.4075
David Grimwade, Helen Walker, Fiona Oliver, Keith Wheatley, Christine Harrison, Georgina Harrison, John Rees, Ian Hann, Richard Stevens, Alan Burnett, Anthony Goldstone, The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial Blood. ,vol. 92, pp. 2322- 2333 ,(1998) , 10.1182/BLOOD.V92.7.2322
Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer, Elihu Estey, Bob Löwenberg, Hervé Dombret, Chatchada Karanes, Matthias Theobald, John M. Bennett, Matthew L. Sherman, Mark S. Berger, Catharine B. Eten, Michael R. Loken, Jacques J.M. van Dongen, Irwin D. Bernstein, Frederick R. Appelbaum, , Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse Journal of Clinical Oncology. ,vol. 19, pp. 3244- 3254 ,(2001) , 10.1200/JCO.2001.19.13.3244
Elihu Estey, Marcos De Lima, Raoul Tibes, Sherry Pierce, Hagop Kantarjian, Richard Champlin, Sergio Giralt, None, Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood. ,vol. 109, pp. 1395- 1400 ,(2007) , 10.1182/BLOOD-2006-05-021907
Mikkael A. Sekeres, Paul Elson, Matt E. Kalaycio, Anjali S. Advani, Edward A. Copelan, Stefan Faderl, Hagop M. Kantarjian, Elihu Estey, Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood. ,vol. 113, pp. 28- 36 ,(2009) , 10.1182/BLOOD-2008-05-157065
Emil J. Freireich, Edmund A. Gehan, David Sulman, Dane R. Boggs, Emil Frei, The effect of chemotherapy on acute leukemia in the human Journal of Chronic Diseases. ,vol. 14, pp. 593- 608 ,(1961) , 10.1016/0021-9681(61)90118-7
Peter Paschka, Core binding factor acute myeloid leukemia. Seminars in Oncology. ,vol. 35, pp. 410- 417 ,(2008) , 10.1053/J.SEMINONCOL.2008.04.011
Elihu H. Estey, Peter F. Thall, New designs for phase 2 clinical trials Blood. ,vol. 102, pp. 442- 448 ,(2003) , 10.1182/BLOOD-2002-09-2937
Sylvie D. Freeman, Jelena V. Jovanovic, David Grimwade, Development of minimal residual disease-directed therapy in acute myeloid leukemia. Seminars in Oncology. ,vol. 35, pp. 388- 400 ,(2008) , 10.1053/J.SEMINONCOL.2008.04.009